Market Overview

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Share:
Related BIIB
Has A Biotech Recovery Started Yet?
The Next Sector Rotation Will Be To Biotechs
The Vetr community has downgraded $BIIB to 4-Stars (Vetr)
Related AMGN
Benzinga's M&A Chatter for Wednesday May 25, 2016
Has A Biotech Recovery Started Yet?
Q1 Picks From Michael Burry - The Man Who Predicted The Mortgage Crisis (Seeking Alpha)

Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.

Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion.

Amgen (NASDAQ: AMGN) is expected to earn $1.80 per share in the September quarter. Amgen's trailing-twelve-month operating margin is 34.08%.

Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) is likely to earn $1.46 per share in the June quarter. Jazz Pharmaceuticals had $387.20 million in total cash for the latest quarter.

Celgene (NASDAQ: CELG) may earn $1.45 per share in the September quarter. Celgene's PEG ratio is 0.94.

Posted-In: Biotechnology Industry Highest EPS Estimates NASDAQ StocksTrading Ideas

 

Related Articles (AMGN + BIIB)

View Comments and Join the Discussion!